IDEXX Laboratories Acquires AI Vet Software Firm CoVetAI
IDEXX Laboratories snapped up AI-native veterinary software provider CoVetAI and set a Q3 2026 earnings date of November 2.
IDEXX Laboratories made a strategic move into artificial intelligence by acquiring CoVetAI Inc., a company that develops AI-native software tailored specifically for veterinary practices, the diagnostics giant confirmed. The deal signals IDEXX's push to embed advanced technology deeper into the day-to-day operations of animal health clinics.
The acquisition positions IDEXX to expand its digital footprint in the veterinary market, where AI-driven workflow tools are increasingly seen as a competitive differentiator. CoVetAI's platform was built from the ground up with artificial intelligence at its core, rather than bolted on after the fact — a distinction that could accelerate integration into IDEXX's existing product ecosystem.
Read more Aura Minerals to Insource Mining Fleet at Three Brazil Gold Mines →
On the financial calendar, IDEXX has scheduled the release of its third-quarter 2026 results for November 2, 2026, giving investors a near-term milestone to watch as they assess how the CoVetAI deal factors into the company's growth outlook. Meanwhile, IDEXX shares traded flat in after-hours activity on the Lang & Schwarz exchange, holding steady at EUR 460.50 with no change from the prior close.
The veterinary software market has drawn growing interest from both established diagnostics players and technology startups, as practices seek tools that can streamline patient records, diagnostic interpretation, and client communication. IDEXX's move to acquire a purpose-built AI vendor rather than develop in-house suggests urgency in keeping pace with that shift.
Continue reading at AD HOC NEWS.
